patient treatment patients clinical wide

The gap

Supporting evidence — 3 representative gaps

• Mechanisms of inflammation in premature ovarian insufficiency and advances in therapeutic studies (2026) · doi

  A substantial body of research evidence suggests that inflammation plays an integral role in the development of premature ovarian failure. Whether it is an imbalance of pro- inflammatory cytokines, aberrant activation of inflammatory signaling pathways, or immune cell-mediated autoimmune ovarian destruction, premature follicular apoptosis and depletion can lead to POI (7, 53). Inflammation may be both a common downstream pathway for different etiologies of POI (e.g. chemotherapeutic injury, autoimmunity, genetic mutations, etc.) and a self-amplifying factor that exacerbates and maintains ovarian decline. Consequently, considering POI as an inflammation-driven disease provides us with a new perspective for integrating various etiological factors. Within this framework, the success of various types of anti-inflammatory interventions in POI models is encouraging. These include glucocorticoids, which are used to suppress autoimmune inflammation; small molecules, which are used to block the release of inflammatory mediators; stem cell t h e r a p i e s , w h i c h a r e u s e d t o r e m o d e l t h e i m m u n e microenvironment; and multi-targeted modulation of natural products from traditional Chinese medicine. The efficacy of these strategies in reducing the inflammatory load of the ovary is evidenced by the restoration of ovarian function. In the future, the introduction of anti-inflammatory concepts in POI treatment is expected to open up new pathways. Yet, there is still a lot that remain to be investigated. Firstly, the POI patient population is highly heterogeneous. It is unknown whether the inflammation is comparable across subtypes. For example, there is a clear lack of large studies to address what proportion of patients with idiopathic POI have significant inflammatory abnormalities. In the future, for patients with ‘inflammation-dominant’ POIs, screening biomarker such as cytokine profiles, inflammation-related immune cell subtypes, gene expression, etc. will be indispensable. Secondly, inflammation is a wide category, and in particular for POI, we need to further refine what inflammatory pathways/factors are ‘cause’ and what are the ‘effect’. For example, we often see upregulation of IL-6 in POI cases; however, it remains unclear if this is a primary event leading to follicular cell death or more of a secondary change? These mechanistic questions can be resolved with access to patient tissues and models, but using histological techniques (single-cell RNA sequencing, proteomics, metabolomics, etc.) will allow us to distinguish between primary and secondary changes. Then, there is a local and systemic relationship that must be highlighted. In these patients, we often see changes in systemic inflammatory markers such as NLR ratio, C-reactive protein, etc., and the inflammatory milieu systemically can be playing a role by endocrine or immune pathways on the ovary; conversely, the hypoestrogenic state induced by ovarian failure can feed back to worsen systemic inflammation. Noting this local vs. systemic causality is critical to developing a holistic treatment strategy. On the clinical translation front, well-designed clinical trials are needed to evaluate the efficacy and safety of various anti- inflammatory therapies in patients with POI. There is currently a

  Keywords: ammatory ammation ovarian cell pathways there patients systemic immune various anti role premature failure whether
• Clinical Predictors of Response to Tocilizumab: A Retrospective Multicenter Study (2022) · doi

  A wide range of the TCZ study outcomes suggested that the response might be related to the clinical and biochemical profile of the patient, but more studies with larger patient groups are required to foresee patients' response to TCZ treatment.

  Keywords: response patient wide range outcomes related clinical biochemical profile larger groups required foresee patients treatment
• Investigating PKD2 deficiency-associated cardiomyopathies using hESC-cardiomyocytes and bioengineered 3D ventricular cardiac tissue strips (2026) · doi

  Currently, there are no targeted treatment strategies for cardiomyopathies in ADPKD patients, leaving an important clinical gap that requires translation of findings into patient therapeutic interventions.

  Keywords: currently there targeted treatment strategies cardiomyopathies adpkd patients leaving important clinical requires translation patient therapeutic